Analyst Research on Celldex Therapeutics Inc. and Immucor Inc. - Diagnostic Substances Hurt by Macro Economy
JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 09/02/11 -- www.stockcall.com/ offers investors comprehensive research on the Diagnostic Substances industry and has completed analytical research on Celldex Therapeutics Inc. (NASDAQ: CLDX) and Immucor Inc. Register with us today at www.stockcall.com/ to have free access to these researches.
Weakness in the macroeconomic landscape has weighed on the Diagnostic Substances sector for some time now. Hospitals have been reining in their budgets due to a great deal of uncertainty in the healthcare markets. This, as well as a decline in patient visits due to the scary employment environment has really hurt demand for some companies in the sector. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the Diagnostic Substances industry.
www.stockcall.com/ is an online platform where investors doing their due-diligence on the Diagnostic Substances industry can have easy and free access to our analyst research and opinions on Immucor Inc. and Celldex Therapeutics Inc.; all investors need to do is register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html.
Toss in a slowdown in the blood industry and it is not surprising to hear that struggling companies like Immucor Inc. are being acquired. The acquirer, TPG Capital is banking on improvement in the blood industry during the coming years as surgery volumes go up due to the large population of baby-boomers reaching their peak time for healthcare needs. Investors looking for free research on Immucor Inc. are welcome to sign up at www.stockcall.com/BLUD020911.pdf for our new report.
As the negative economic landscape makes acquisitions attractive to TPG, now could also be a good time for investors to enter the market. Companies like Celldex Therapeutics Inc. have seen a pullback in their stock prices that do not seem to relate directly to negative announcements about drug trials. Considering the grand scope of several cancer drugs the company is currently developing, this may be an opportunity for investors to hit it big. Investors looking for complimentary research on Celldex Therapeutics Inc. are welcome to sign up at www.stockcall.com/CLDX020911.pdf for our new report.
Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.
William T. Knight